Clinical and Pharmaco Diagnostics - Colon
With 655,000 deaths worldwide per year, colon cancer is the fourth most common form of cancer in the United States and the third leading cause of cancer-related death in the Western world.
Source :WHO
Globocan 2008
Colorectal cancers arise from adenomatous polyps in the colon. These mushroom-shaped growths are usually benign, but some develop into cancer over time. Localized colon cancer is usually diagnosed through colonoscopy.
Current colon cancer treatment for patients with localized disease includes surgery, followed in many cases by adjuvant chemotherapy. The use of chemotherapy in stage II tumors is a subject of debate. Stage II colon cancer is subjectively treated based on a risk assessment that utilizes few established clinical and pathologic markers currently available. Most of stage II cancer patients are cured by surgery alone, and only a small percentage, approximately 25%, will experience disease recurrence and may benefit from chemotherapy.
MDxHealth has established an extensive program in the field of colon cancer including biomarkers for the assessment of recurrence risk following surgery in localized colon cancer patients and for therapy guidance in advanced colon cancer. We are developing two products in the colon cancer field to help identify aggressive disease and to help in treatment decisions.
| US incidence of Colorectum Cancer | 153,881/Year (all stages) |
| EU (27) incidence of Colorectum Cancer | 333,330/Year (all stages) |
| Global incidence of Colorectum Cancer | 1,233,711/Year (all stages) |
Product
InformMDx for Colon Cancer is a molecular prognostic test which will provide physicians with a tool to aid in the assessment of the patient’s prognosis; the aggressiveness of the tumor and risk of recurrence after surgery. The test provides a new method for identification of Stage II colon cancer patients who are likely to recur. This test, in conjunction with traditional risk factors, will help physicians select those patients who may benefit from more aggressive treatment including chemotherapy.
Literature
Louwagie J., Pommerie, W. Brichard G., Otto, G, Van Criekinge, W., Baylin, S., Ahuja, N, Adams H-P, Nürnberg, D., Bierau, K.:. A Plasma-based colorectal cancer (CRC) screening assay using DNA methylation markers - first results of multicenter studies; 15th Congress of the European Cancer Organization and 34th Congress of the European Society for Medical Oncology September 2009, Berlin, Germany.
Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, Ahuja N, Herman JG, Baylin SB., Comparing the DNA hypermethylome with gene mutations in human colorectal cancer., PLoS Genet. 2007;3(9):1709-23.
Jubb AM, Bell SM, Quirke P. Methylation and colorectal cancer., J Pathol. 2005;195(1):111-134 Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97(15):1124-32.
Schuebel K, Chen W, Baylin SB. CIMPle origin for promoter hypermethylation in colorectal cancer? Nat Genet. 2006;38(7):738-40.
MDxHealth’s products are not currently cleared or approved by the FDA.